Trial Profile
A randomized, open-label, single-centre drug-drug interaction Phase 1 study to assess the safety, tolerability and pharmacokinetics of OBE022 when co-administered with medications typically used in women with pre-term labour
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2019
Price :
$35
*
At a glance
- Drugs Ebopiprant (Primary) ; Atosiban; Betamethasone; Magnesium sulfate; Nifedipine
- Indications Preterm labour
- Focus Adverse reactions; Pharmacokinetics
- 19 Mar 2019 Results published in the British Journal of Clinical Pharmacology
- 25 May 2017 New trial record
- 18 May 2017 Results published in an ObsEva media release.